Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 4, 2008, Pages 713-719

  Kurabachew, Mekonnen ^a   Lu, Stephen H J ^a   Krastel, Philipp ^b   Schmitt, Esther K ^b   Suresh, Bangalore L ^a   Goh, Anne ^a   Knox, John E ^a   Ma, Ngai Ling ^a   Jiricek, Jan ^a   Beer, David ^a   Cynamon, Michael ^c   Petersen, Frank ^b   Dartois, Veronique ^a   Keller, Thomas ^a   Dick, Thomas ^a   Sambandamurthy, Vasan K ^a,d  

^a NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

^b NOVARTIS PHARMA AG   (Switzerland)

^c SYRACUSE VA MEDICAL CENTER   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Antimycobacterial activity; Resistance mechanism; Transcription

Indexed keywords

ISONIAZID; LIPIARMYCIN; MOXIFLOXACIN; NUCLEOTIDYLTRANSFERASE; PROTEIN RPOC; RIFAMPICIN; RNA POLYMERASE; RNA POLYMERASE BETA SUBUNIT; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; DRUG TARGETING; ENZYME INHIBITION; GENE SEQUENCE; MINIMUM INHIBITORY CONCENTRATION; MISSENSE MUTATION; MULTIDRUG RESISTANCE; MUTANT; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; SEQUENCE ANALYSIS;

ADAPTATION, BIOLOGICAL; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINOGLYCOSIDES; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DNA MUTATIONAL ANALYSIS; DNA, BACTERIAL; DNA-DIRECTED RNA POLYMERASES; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 52949083239     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn269     Document Type: Article

References (24)

1. Global tuberculosis control - surveillance, planning, financing. WHO Report, 2008, WHO/HTM/TB/2008.393. http://www.who.int/tb/publications/ global_report/en/ (15 May 2008, date last accessed).
2. Zignol M, Hósseini MS, Wright A et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006; 194: 479-85.
3. Matteelli A, Migliori GB, Cirillo D et al. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: Epidemiology and control. Expert Rev Anti Infect Ther 2007; 5: 857-71.
4. Sarubbi E, Monti F, Corti E et al. Mode of action of the microbial metabolite GE23077, a novel potent and selective inhibitor of bacterial RNA polymerase. Eur J Biochem 2004; 271: 3146-54.
5. Villain-Guillot P, Bastide L, Gualtieri M et al. Progress in targeting bacterial transcription. Drug Discov Today 2007; 12 200-8.
6. Floss HG, Yu TW. Rifamycin-mode of action, resistance, and biosynthesis. Chem Rev 2005; 105: 621-32.
7. Mitchison DA. The search for new sterilizing anti-tuberculosis drugs. Front Biosci 2004; 9: 1059-72.
8. O'Neill A, Oliva B, Storey C et al. RNA polymerase inhibitors with activity against rifampin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother 2000; 44: 3163-6.
9. Chopra I. Bacterial RNA polymerase: A promising target for the discovery of new antimicrobial agents. Curr Opin Investig Drugs 2007; 8 600-7.
10. Strohl WR. The role of natural products in a modern drug discovery program. Drug Discov Today 2000; 5: 39-41.
11. Butler MS. Natural products to drugs: Natural product derived compounds in clinical trials. Nat Prod Rep 2005; 22: 162-95.
12. Hochlowski JE, Swanson SJ, Ranfranz LM et al. Tiacumicins, a novel complex of 18-membered macrolides. II. Isolation and structure determination. J Antibiot (Tokyo) 1987; 40: 575-88.
13. Credito KL, Appelbaum PC. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother 2004; 48: 4430-4.
14. Johnson AP. Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic. Curr Opin Investig Drugs 2007; 8: 168-73.
15. Gualtieri M, Villain-Guillot P, Latouche J et al. Mutation in the Bacillus subtilis RNA polymerase β′ subunit confers resistance to lipiarmycin. Antimicrob Agents Chemother 2006; 50: 401-2.
16. Sonenshein AL, Alexander HB. Initiation of transcription in vitro inhibited by lipiarmycin. J Mol Biol 1979; 127: 55-72.
17. Stover CK, de la Cruz VF, Fuerst TR et al. New use of BCG for recombinant vaccines. Nature 1991; 351: 456-60.
18. Kurabachew M, Enger O, Sandaa RA et al. A multiplex polymerase chain reaction assay for genus-, group- and species-specific detection of mycobacteria. Diagn Microbiol Infect Dis 2004; 49: 99-104.
19. Cavusoglu C, Hilmioglu S, Guneri S et al. Characterization of rpoB mutations in rifampin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey by DNA sequencing and line probe assay. J Clin Microbiol 2002; 40: 4435-8.
20. Coronelli C, White RJ, Lancini GC et al. Lipiarmycin, a new antibiotic from Actinoplanes. II. Isolation, chemical, biological and biochemical characterization. J Antibiot (Tokyo) 1975; 28 253-9.
21. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Fifth Edition: Approved Standard M7-A5. NCCLS, Wayne, PA, USA, 2000.
22. Mariam DH, Mengistu Y, Hpffner SE et al. Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2004; 48: 1289-94.
23. Vassylyev DG, Sekine S, Laptenko O et al. Crystal structure of a bacterial RNA polymerase holoenzyme at 2.6 Å resolution. Nature 2002; 417: 712-9.
24. Chan ED, Iseman MD. Current medical treatment for tuberculosis. Br Med J 2002; 325: 1282-6.